SCHEMBL4767302

SCHEMBL4767302

CCCCNC1CNCC[N]1

nearest known ligand 0.39

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 3/20 0.39
GNAO1 P09471 3/20 0.39
GNAI1 P63096 3/20 0.39
KCNH2 Q12809 1/20 0.32
FUCA1 P04066 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7509499 0.93 GNAI3 (0.47) GNAI3GNAO1GNAI1FUCA1
SCHEMBL4721976 0.89 KCNH2 (0.34) GNAI3GNAO1GNAI1KCNH2
SCHEMBL4722966 0.81
SCHEMBL4724462 0.72 CYP2D6 (0.32)
SCHEMBL4721777 0.72 GNAI3 (0.34) GNAI3GNAO1GNAI1FUCA1
SCHEMBL7508582 0.71 GNAI3 (0.51) GNAI3GNAO1GNAI1
SCHEMBL4723878 0.70 GNAI3 (0.37) GNAI3GNAO1GNAI1FUCA1
SCHEMBL4723807 0.70 MEN1 (0.36) GNAI3GNAO1GNAI1FUCA1
SCHEMBL4723537 0.70
SCHEMBL789435 0.69 NOS1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 GNAI3 936/4885GNAO1 1763/4885GNAI1 1407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.